A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

Authors

• William Kelly

Publication/Presentation Date

5-2014

Volume

32

Issue

15

Published In/Presented At

DOI: 10.1200/jco.2014.32.15_suppl.tps5107

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article